Guangzhong Yang1, Wenming Chen, Yin Wu. 1. Department of Hematology & Multiple Myeloma Research Center of Beijing, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing 100020, China.
Abstract
OBJECTIVE: To investigate the efficacy and safety of the treatment of the newly diagnosed multiple myeloma (MM) with or without renal impairment receiving the therapy of bortezomib, dexamethasone plus thalidomide (BTD) regimen in order to analyze the effects of BTD regimen on the prognosis of the MM patients with renal impairment compared with the patients without renal impairment. METHODS: Seventy-two newly diagnosed MM patients entered into our study and all the patients belonged to International Stage System (ISS) 3 in which transplantation patients were excluded or the patients refused receiving transplantation therapy. According to the level of serum creatinine (Scr), the patients were divided into two groups including group 1 (n=42) (Scr <2 mg/dL) and group 2 (n=30) (Scr ≥2 mg/dL). All the patients received the therapy of BTD regimen as induction therapy, and the median treatment time was 5 (range, 2-8) cycles. The outcome was analyzed retrospectively. RESULTS: The overall remission (OR) rates were 81.0% (group 1) and 80.0% (group 2). There was no statistical difference between the two groups (P>0.05). In group 2, 10 patients (33.3%) got renal function reversal, 14 patients (46.7%) got improved renal function and the median time to renal function reversal was 1.4 (range, 0.7-3.0) months. Among 12 patients with hemodialysis at diagnosis, 8 patients got rid of hemodialysis after median 4 cycles of therapy (range, 3-6 cycles). After a median follow-up period of 16 (range, 2-31) months, 5 patients (11.9%) in group 1 died and 9 patients (30.0%) in group 2 died (P=0.056). The 2-year estimate of overall survival was 77.3% in group 1 and 63.8% in group 2, respectively (P=0.188). During a median follow-up time of 13.0 months (range, 2-25 months), 15 patients (35.7%) in group 1 progressed and 13 patients (43.3%) in group 2 progressed (P=0.513). The 2-year estimate of response duration was 50.6% in group 1 and 42.1% in group 2, respectively (P=1). The main toxicities in the two groups included thrombocytopenia, peripheral neuropathy (PN), infection, herpes zoster and so on. The incidence of grade 3 and 4 adverse events was low. CONCLUSIONS: BTD regimen may become the front-line therapy for the newly diagnosed MM patients with renal impairment because BTD regimen can improve the prognosis of the patients with renal impairment as good as the patients without renal impairment.
OBJECTIVE: To investigate the efficacy and safety of the treatment of the newly diagnosed multiple myeloma (MM) with or without renal impairment receiving the therapy of bortezomib, dexamethasone plus thalidomide (BTD) regimen in order to analyze the effects of BTD regimen on the prognosis of the MMpatients with renal impairment compared with the patients without renal impairment. METHODS: Seventy-two newly diagnosed MMpatients entered into our study and all the patients belonged to International Stage System (ISS) 3 in which transplantation patients were excluded or the patients refused receiving transplantation therapy. According to the level of serum creatinine (Scr), the patients were divided into two groups including group 1 (n=42) (Scr <2 mg/dL) and group 2 (n=30) (Scr ≥2 mg/dL). All the patients received the therapy of BTD regimen as induction therapy, and the median treatment time was 5 (range, 2-8) cycles. The outcome was analyzed retrospectively. RESULTS: The overall remission (OR) rates were 81.0% (group 1) and 80.0% (group 2). There was no statistical difference between the two groups (P>0.05). In group 2, 10 patients (33.3%) got renal function reversal, 14 patients (46.7%) got improved renal function and the median time to renal function reversal was 1.4 (range, 0.7-3.0) months. Among 12 patients with hemodialysis at diagnosis, 8 patients got rid of hemodialysis after median 4 cycles of therapy (range, 3-6 cycles). After a median follow-up period of 16 (range, 2-31) months, 5 patients (11.9%) in group 1 died and 9 patients (30.0%) in group 2 died (P=0.056). The 2-year estimate of overall survival was 77.3% in group 1 and 63.8% in group 2, respectively (P=0.188). During a median follow-up time of 13.0 months (range, 2-25 months), 15 patients (35.7%) in group 1 progressed and 13 patients (43.3%) in group 2 progressed (P=0.513). The 2-year estimate of response duration was 50.6% in group 1 and 42.1% in group 2, respectively (P=1). The main toxicities in the two groups included thrombocytopenia, peripheral neuropathy (PN), infection, herpes zoster and so on. The incidence of grade 3 and 4 adverse events was low. CONCLUSIONS:BTD regimen may become the front-line therapy for the newly diagnosed MMpatients with renal impairment because BTD regimen can improve the prognosis of the patients with renal impairment as good as the patients without renal impairment.
Authors: María-Victoria Mateos; José-M Hernández; Miguel-T Hernández; Norma-C Gutiérrez; Luis Palomera; Marta Fuertes; Joaquín Díaz-Mediavilla; Juan-J Lahuerta; Javier de la Rubia; María-José Terol; Ana Sureda; Joan Bargay; Paz Ribas; Felipe de Arriba; Adrian Alegre; Albert Oriol; Dolores Carrera; José García-Laraña; Ramón García-Sanz; Joan Bladé; Felipe Prósper; Gemma Mateo; Dixie-Lee Esseltine; Helgi van de Velde; Jesús-F San Miguel Journal: Blood Date: 2006-06-13 Impact factor: 22.113
Authors: Sundar Jagannath; Brian G M Durie; Jeffrey Wolf; Elber Camacho; David Irwin; Jose Lutzky; Marti McKinley; Eli Gabayan; Amitabha Mazumder; David Schenkein; John Crowley Journal: Br J Haematol Date: 2005-06 Impact factor: 6.998
Authors: Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin Journal: J Clin Oncol Date: 2005-04-04 Impact factor: 44.544
Authors: Fortunato Morabito; Massimo Gentile; Stefania Ciolli; Maria T Petrucci; Sara Galimberti; Giuseppe Mele; Antonio F Casulli; Donato Mannina; Eugenio Piro; Graziella Pinotti; Salvatore Palmieri; Lucio Catalano; Vincenzo Callea; Massimo Offidani; Pellegrino Musto; Sara Bringhen; Luca Baldini; Patrizia Tosi; Francesco Di Raimondo; Mario Boccadoro; Antonio Palumbo; Michele Cavo Journal: Eur J Haematol Date: 2009-11-23 Impact factor: 2.997
Authors: J Bladé; P Fernández-Llama; F Bosch; J Montolíu; X M Lens; S Montoto; A Cases; A Darnell; C Rozman; E Montserrat Journal: Arch Intern Med Date: 1998-09-28
Authors: Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp Journal: Mayo Clin Proc Date: 2003-01 Impact factor: 7.616